Cabeza-Segura, Manuel
Gambardella, Valentina
Gimeno-Valiente, Francisco
Carbonell-Asins, Juan Antonio
Alarcón-Molero, Lorena
González-Vilanova, Arturo
Zuñiga-Trejos, Sheila
Rentero-Garrido, Pilar
Villagrasa, Rosana
Gil, Mireia
Durá, Ana
Richart, Paula
Alonso, Noelia
Huerta, Marisol
Roselló, Susana
Roda, Desamparados
Tarazona, Noelia
Martínez-Ciarpaglini, Carolina
Castillo, Josefa
Cervantes, Andrés http://orcid.org/0000-0003-3806-3691
Fleitas, Tania http://orcid.org/0000-0002-2789-9082
Funding for this research was provided by:
AECC: Asociación Española contra el cáncer: Spanish organization
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (JR21/00042, PI18/01909, JR16/00040, PI21/00689, JR20/00005, PI21/00695, PI18/01508, PI21/0693, JR17/00026)
Generalitat Valenciana (APOSTD/2021/168)
Instituto Carlos III
academic founding
Article History
Received: 9 May 2022
Revised: 18 September 2022
Accepted: 27 September 2022
First Online: 17 October 2022
Competing interests
: AC declares institutional research funding from Genentech, Merck Serono, BMS, MSD, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, Natera and Fibrogen and advisory board or speaker fees from Amgem, Merck Serono, Roche, Bayer, Servier and Pierre Fabre in the last 5 years. All remaining authors have declared no conflict of interest.
: The study was approved by the institutional review board of INCLIVA (Approval ID: CEIC-2018.054). The study was conducted in accordance with the declaration of Helsinki, and was approved by the institutional review board. Written informed consent was obtained from all patients to perform the molecular analysis.
: Not applicable.